The exercise period for warrants of series TO2 starts today
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.
Today, October 4, 2023 the exercise period for warrants of series TO2 begins in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The exercise period lasts until October 18, 2023.
Summarized terms for the warrants of series TO2:
Exercise period: October 4, 2023 – October 18, 2023.
Issue volume: 2,049,966 warrants of series TO2 entitle the holder to subscribe for 2,213,963 shares of series B. Upon full utilization, the Company will receive approximately SEK 0.37 million before issue costs.
Subscription price: 0.18 SEK per share.
Last day for trading with warrants of series TO2: October 13, 2023.
Share capital and dilution: Upon full exercise of the warrants, the share capital will increase by SEK 391,871.45, from SEK 11,719,858.53 to SEK 12,111,729.98. The number of shares increases upon full exercise by 2,213,963 shares, from 66,213,890 shares to 68,427,853 shares. The dilution at full utilization amounts to approximately 3.24 percent of the existing number of shares and votes in the Company.
Please note that the warrants that are not exercised no later than October 18, 2023, or disposed of no later than October 13, 2023, will expire worthless. In order for the warrants not to expire, active subscription of shares or disposal of the warrants is required.
How the warrants are used to subscribe for new shares in the Company:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
Mangold Fondkommission AB is financial advisor to Pharmacolog in connection with the utilization of warrants. Eversheds Sutherland Advokatbyrå AB is legal advisor to the Company in connection with the utilization of warrants.
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The company’s Certified Adviser is Mangold Fondkommission AB.
The publication, announcement or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from anyone else.
This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland, the United States, Belarus, Russia or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.